Mobia Medical’s (MOBI) Buy Rating Reiterated at BTIG Research

Mobia Medical (NASDAQ:MOBI)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued on Tuesday, Benzinga reports. They presently have a $19.00 price target on the stock. BTIG Research‘s price objective points to a potential upside of 110.18% from the company’s previous close.

Several other brokerages also recently weighed in on MOBI. Weiss Ratings began coverage on Mobia Medical in a research report on Wednesday, August 12th. They set a “sell (e-)” rating for the company. JPMorgan Chase & Co. increased their target price on Mobia Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.75.

Mobia Medical Price Performance

Shares of MOBI stock traded up $0.23 on Tuesday, hitting $9.04. 62,849 shares of the company’s stock were exchanged, compared to its average volume of 173,490. The company has a debt-to-equity ratio of 0.04, a quick ratio of 12.80 and a current ratio of 13.28. Mobia Medical has a 12 month low of $8.03 and a 12 month high of $15.29. The company has a market capitalization of $300.94 million and a PE ratio of -0.45. The stock’s 50 day moving average is $10.14.

Mobia Medical (NASDAQ:MOBI) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.27). The company had revenue of $13.51 million during the quarter. The company’s quarterly revenue was up 102.4% on a year-over-year basis. Sell-side analysts predict that Mobia Medical will post -2.63 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Casey Tansey bought 35,572 shares of the company’s stock in a transaction on Thursday, August 13th. The stock was purchased at an average cost of $11.51 per share, for a total transaction of $409,433.72. Following the completion of the transaction, the director owned 268,904 shares of the company’s stock, valued at $3,095,085.04. This trade represents a 15.25% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders bought 87,000 shares of company stock valued at $1,016,367 in the last ninety days.

Hedge Funds Weigh In On Mobia Medical

Large investors have recently bought and sold shares of the company. State Street Corp bought a new position in Mobia Medical in the second quarter valued at about $735,000. Citadel Advisors LLC bought a new position in Mobia Medical in the second quarter valued at about $670,000. Finally, Readystate Asset Management LP bought a new position in Mobia Medical in the second quarter valued at about $134,000.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.